The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor Opdivo, which was approved for this indication as monotherapy in 2015 and in combination with the CTLA-4 inhibitor Yervoy in 2018, has revolutionized clinical practice. Although existing treatment options aim to improve PFS, significant need remains for well-tolerated therapies that can extend the OS and PFS of patients with advanced or metastatic renal cell carcinoma.

QUESTIONS ANSWERED

  • What are the treatment drivers that are most likely to influence a therapy’s uptake for advanced or metastatic renal cell carcinoma?
  • How do current therapies for advanced or metastatic renal cell carcinoma perform on key attributes?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across key clinical attributes and price when considering hypothetical new treatment options for advanced or metastatic renal cell carcinoma?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Table of contents

  • Renal Cell Carcinoma - Unmet Need - Detailed, Expanded Analysis: Metastatic Renal Cell Carcinoma
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
        • Regimens for First-Line Advanced or Metastatic Renal Cell Carcinoma
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Oncologists' Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma
      • Importance of Efficacy Attributes to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Importance of Efficacy Attributes to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Importance of Requirement for Comedication to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Importance of Requirement for Comedication to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Key Findings: Stated vs. Derived Importance
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Advanced or Metastatic Renal Cell Carcinoma: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
      • Overall Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma: United States
      • Overall Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Relative Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma Across Select Efficacy Attributes: United States
      • Relative Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma Across Select Efficacy Attributes: Europe
      • Relative Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma Across Select Safety and Tolerability Attributes: United States
      • Relative Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma Across Select Safety and Tolerability Attributes: Europe
      • Relative Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma Across Select Convenience of Administration Attributes: United States
      • Relative Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Advanced or Metastatic Renal Cell Carcinoma
      • Surveyed Medical Oncologists' Satisfaction with the Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
      • Surveyed Medical Oncologists' Satisfaction with the Performance of Key Therapies for Advanced or Metastatic Renal Cell Carcinoma on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Advanced or Metastatic Renal Cell Carcinoma: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Advanced or Metastatic Renal Cell Carcinoma: Europe
      • Key Findings: Unmet Need in Advanced or Metastatic Renal Cell Carcinoma and Related Indications
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Advanced or Metastatic Renal Cell Carcinoma and Related Indications: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Advanced or Metastatic Renal Cell Carcinoma and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Advanced or Metastatic Renal Cell Carcinoma Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy That Can Extend Survival
        • Opportunity: A Novel Therapy That Can Improve Progression-Free Survival
        • Opportunity: A Novel Therapy with an Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • First-Line Advanced or Metastatic Renal Cell Carcinoma Target Product Profile: Attribute Importance
        • Median Overall Survival
        • Median Progression-Free Survival
        • Incidence of Grade 3/4 Clinical Chemistry and Metabolic Abnormalities
        • Incidence of Grade 3/4 Gastrointestinal Toxicities
        • Incidence of Grade 3/4 Hematological Toxicities
        • Incidence of Grade 3/4 Cardiovascular Toxicities
        • Price per 28-Day Cycle
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Advanced or Metastatic Renal Cell Carcinoma Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Advanced or Metastatic Renal Cell Carcinoma Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • First-Line Advanced or Metastatic Renal Cell Carcinoma Market Simulations: Target Product Profiles Included in Scenario 1
        • Advanced or Metastatic Renal Cell Carcinoma Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Advanced or Metastatic Renal Cell Carcinoma Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • First-Line Advanced or Metastatic Renal Cell Carcinoma Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Khurram Nawaz, MSc

Khurram Nawaz is a director in the oncology team at Decision Resources Group. Mr. Nawaz manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. He also provides sales and client support on syndicated and custom oncology products, translating domain knowledge into actionable insights.

Previously, Mr. Nawaz was a principal analyst in the oncology team at Decision Resources Group, where he developed considerable expertise in forecasting complex oncology and hemato-oncology drug markets, and conducted detailed primary research with physicians and payers across multiple geographies. He has in-depth expertise in immuno-oncology, non-small-cell lung cancer, prostate cancer, multiple myeloma, and other solid and hematological malignancies. Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders. He holds a M.Sc. in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a B.Sc. in life sciences from the Pierre and Marie Curie–Paris VI University.


Related Reports

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | DLSFON0009-2020

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Emerging Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of...

View Details

Renal Cell Carcinoma - Epidemiology - Europe

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 count...

View Details